Guardant Health is a biotechnology company that specializes in developing advanced genomic tests for cancer patients. The company focuses on providing innovative liquid biopsy solutions, which involve analyzing circulating tumor DNA from blood samples to help detect and monitor cancers more effectively. Their tests are designed to aid physicians in making informed treatment decisions, enabling personalized medicine approaches that can improve patient outcomes. Through their cutting-edge technology and extensive research, Guardant Health aims to transform cancer care by delivering actionable insights and facilitating early detection and ongoing management of the disease. Read More
Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $3...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
Diagnostics company Guardant Health (NASDAQ:GH) will be announcing earnings results this Thursday after market close. Here’s what to look for. Guardant Healt...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of a new video featuring actor and cancer advocate Patrick Dempsey that highlights the more than 55,000 Americans who will lose their lives to colorectal cancer (CRC) this year1, a majority of which will not have been up to date with their colorectal cancer screening.2
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 5.4% in the afternoon session after several investment firms issued positive ...
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 6.1% in the morning session after its stock hit a 52-week high following rece...
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option.
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
Over the past six months, Guardant Health has been a great trade, beating the S&P 500 by 11.7%. Its stock price has climbed to $129.08, representing a health...
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industr...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests.
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
